Aflibercept for the treatment of neovascular age-related macular degeneration

Drugs of Today

Volumn 48, Issue 5, 2012, Pages 317-329

  Verner Cole, E A ^a   Davis, S J ^a   Lauer, Andreas K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aflibercept; Age related macular degeneration; Vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PLACEBO; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLEPHARITIS; BLURRED VISION; BRONCHITIS; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; CORNEA INJURY; DIABETIC MACULAR EDEMA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; EYE PAIN; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; MAXIMUM TOLERATED DOSE; NONHUMAN; OCULAR HYPEREMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; REFRACTION ERROR; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA DISEASE; RETINA EDEMA; RETINA FIBROSIS; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA TEAR; REVIEW; SIDE EFFECT; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VISUAL ACUITY; VISUAL DISORDER; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DIABETES COMPLICATIONS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84861980737     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.5.1805931     Document Type: Review

References (51)

1. Cong, R., Zhou, B., Sun, Q., Gu, H., Tang, N., Wang, B. Smoking and the risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 2008, 18(8): 647-56. (Pubitemid 352001387)
2. Friedman, D.S., O'Colmain, B.J., Munoz, B. et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004, 122(4): 564-72. (Pubitemid 38456293)
3. Ferris, F.L., 3rd, Fine, S.L., Hyman, L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984, 102(11): 1640-2. (Pubitemid 15204559)
4. Klein, R., Klein, B.E., Linton, K.L., DeMets, D.L. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol 1993, 137(2): 190-200. (Pubitemid 23083671)
5. Kwak, N., Okamoto, N., Wood, J.M., Campochiaro, P.A. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000, 41(10): 3158-64.
6. Krzystolik, M.G., Afshari, M.A., Adamis, A.P. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002, 120(3): 338-46. (Pubitemid 34250056)
7. Lopez, P.F., Sippy, B.D., Lambert, H.M., Thach, A.B., Hinton, D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996, 37(5): 855-68.
8. Ferrara, N., Gerber, H.P., LeCouter, J. The biology of VEGF and its receptors. Nat Med 2003, 9(6): 669-76. (Pubitemid 36749215)
9. Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J., Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992, 267(36): 26031-7. (Pubitemid 23014012)
10. Terman, B.I., Carrion, M.E., Kovacs, E., Rasmussen, B.A., Eddy, R.L., Shows, T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6(9): 1677-83. (Pubitemid 21924273)
11. Chung, A.S., Lee, J., Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010, 10(7): 505-14.
12. Emerson, M.V., Lauer, A.K. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2008, 2(2): 377-88.
13. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Jr., Feinsod, M., Guyer, D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004, 351(27): 2805-16. (Pubitemid 40051904)
14. Ferrara, N., Damico, L., Shams, N., Lowman, H., Kim, R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26(8): 859-70. (Pubitemid 44547437)
15. Rosenfeld, P.J., Moshfeghi, A.A., Puliafito, C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005, 36(4): 331-5. (Pubitemid 41073112)
16. Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., Kim, R.Y. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006, 355(14): 1419-31. (Pubitemid 44511557)
17. Brown, D.M., Kaiser, P.K., Michels, M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355(14): 1432-44. (Pubitemid 44511558)
18. Fung, A.E., Lalwani, G.A., Rosenfeld, P.J. et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007, 143(4): 566-83.
19. Ziemssen, F., Grisanti, S., Bartz-Schmidt, K.U., Spitzer, M.S. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Drugs Aging 2009, 26(4): 295-320.
20. Martin, D.F., Maguire, M.G., Ying, G.S., Grunwald, J.E., Fine, S.L., Jaffe, G.J. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011, 364(20): 1897-908.
21. Singer, M.A., Awh, C.C., Sadda, S., Freeman, W.R., Antoszyk, A.N., Wong, P., Tuomi, L. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012, epub ahead of print.
22. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R D 2008, 9(4): 261-9.
23. Holash, J., Davis, S., Papadopoulos, N. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99(17): 11393-8. (Pubitemid 34920936)
24. Dixon, J.A., Oliver, S.C., Olson, J.L., Mandava, N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2009, 18(10): 1573-80.
25. Yu, L., Liang, X.H., Ferrara, N. Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 2011, 408(2): 276-81.
26. Regeneron announces FDA approval of EYLEA(TM) (aflibercept) injection for the treatment of wet age-related macular degeneration [news release]. Regeneron Pharmaceuticals Inc., November 18, 2011. Accessed May 10, 2012.
27. EYLEA(TM) (aflibercept injection) submitted in Japan for marketing authorization for the treatment of wet age-related macular degeneration [news release]. Regeneron Pharmaceuticals Inc., June 28, 2011. Accessed May 10, 2012.
28. VEGF Trap-Eye submitted for EU marketing authorization for treatment of wet age-related macular degeneration [news release]. Regeneron Pharmaceuticals Inc., June 7, 2011. Accessed May 10, 2012.
29. Regeneron and Bayer announce approval of EYLEA(R) (aflibercept) injection for the treatment of wet age-related macular degeneration in Australia [news release]. Regeneron Pharmaceuticals Inc., March 8, 2012. Accessed May 10, 2012.
30. Saishin, Y., Takahashi, K., Lima e Silva, R., Hylton, D., Rudge, J.S., Wiegand, S.J., Campochiaro, P.A. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003, 195(2): 241-8. (Pubitemid 36384298)
31. Cao, J., Zhao, L., Li, Y. et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci 2010, 51(11): 6009-17.
32. Lutty, G.A., McLeod, D.S., Bhutto, I., Wiegand, S.J. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 2011, 52(7): 4039-47.
33. Nork, T.M., Dubielzig, R.R., Christian, B.J. et al. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol 2011, 129(8): 1042-52.
34. Thai, H.T., Veyrat-Follet, C., Vivier, N., Dubruc, C., Sanderink, G., Mentre, F., Comets, E. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol 2011, 72(3): 402-14.
35. Rudge, J.S., Holash, J., Hylton, D. et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007, 104(47): 18363-70. (Pubitemid 350210713)
36. Nguyen, Q.D., Shah, S.M., Hafiz, G. et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006, 113(9): 1522 e1-e14.
37. Stewart, M.W., Rosenfeld, P.J. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008, 92(5): 667-8. (Pubitemid 351684178)
38. Lockhart, A.C., Rothenberg, M.L., Dupont, J. et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010, 28(2): 207-14.
39. Mordenti, J., Cuthbertson, R.A., Ferrara, N. et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999, 27(5): 536-44. (Pubitemid 29446822)
40. Gaudreault, J., Fei, D., Rusit, J., Suboc, P., Shiu, V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005, 46(2): 726-33. (Pubitemid 40270359)
41. Stewart, M.W. Predicted biologic activity of intravitreal bevacizumab. Retina 2007, 27(9): 1196-200. (Pubitemid 350211524)
42. Nguyen, Q.D., Shah, S.M., Browning, D.J. et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009, 116(11): 2141-8 e1.
43. Brown, D.M., Heier, J.S., Ciulla, T. et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011, 118(6): 1089-97.
44. Heier, J.S., Boyer, D., Nguyen, Q.D. et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011, 118(6): 1098-106.
45. Regeneron Pharmaceuticals Inc. VEGF Trap-Eye (aflibercept ophthalmic solution) Briefing Document. June 17, 2011. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259143.pdf. Accessed March 22, 2012.
46. Do, D.V., Nguyen, Q.D., Shah, S.M. et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009, 93(2): 144-9.
47. Fong, D.S., Strauber, S.F., Aiello, L.P. et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007, 125(4): 469-80. (Pubitemid 46596718)
48. Do, D.V., Schmidt-Erfurth, U., Gonzalez, V.H. et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011, 118(9): 1819-26.
49. Boyer, D.M. Anti-VEGF therapy for CRVO: COPERNICUS study. Paper presented at Angiogenesis, Exudation and Degeneration 2011 (Feb 12, Miami) 2011,
50. Regeneron and Bayer report positive results for VEGF Trap-Eye in second phase 3 study in central retinal vein occlusion [news release]. Regeneron Pharmaceuticals, Inc., April 27, 2011. Accessed May 7, 2012.
51. Study of bimonthly VEGF Trap-eye compared to as-needed administration or other therapy for exudative age-related macular degeneration (NCT01526070). ClinicalTrials.gov Web site, Accessed May 7, 2012.